Recent Quotes (30 days)

You have no recent quotes
chg | %

Shire PLC  

(Public, LON:SHP)   Watch this stock  
Find more results forSHP
+8.50 (0.25%)
Jan 19 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 3,458.00 - 3,529.00
52 week 3,403.50 - 5,067.00
Open 3,489.50
Vol / Avg. 0.00/2.52M
Mkt cap 31,582.94M*
P/E 27.06
Div/yield 3.85*
EPS 1.28*
Shares 909.78M
Beta     -
Inst. own     -
Feb 14, 2018
Full Year 2017 Shire PLC Earnings Release Add to calendar
Jan 8, 2018
Shire PLC at JPMorgan Healthcare Conference (Q&A Session)
Jan 8, 2018
Shire PLC at JPMorgan Healthcare Conference - Webcast
Oct 27, 2017
Q3 2017 Shire PLC Earnings Call
Oct 27, 2017
Q3 2017 Shire PLC Earnings Release

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 15.00% 5.37%
Operating margin 19.16% 8.45%
EBITD margin - 30.21%
Return on average assets 3.30% 1.46%
Return on average equity 6.92% 3.11%
Employees 23,906 -
CDP Score - B


Miesian Plaza 50-58 Baggot Street Lower, Block 2
+353-1-6096000 (Phone)
+44-1256-894708 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 59
Thomas Dittrich Chief Financial Officer, Executive Director
Age: 53
John Miller Interim Chief Financial Officer
Joanne Cordeiro Chief Human Resource Officer
Andreas Busch Ph.D. Executive Vice President - Head of Research and Development, Chief Scientific Officer
Age: 54
Gisele Dion Chief Accounting Officer, Corporate Controller
Age: 51
William Mordan General Counsel, Company Secretary
Age: 47
Howard Mayer M.D. Chief Medical Officer
Perry Sternberg Head - U.S. Commercial
Age: 48
Kim Stratton Head - International Commercial
Age: 54